Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatic Malignancies Clear all
Completed Phase 2 Interventional Results available

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

NCT03366155
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Interventions
Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex, Oxaliplatin, 5FU, Irinotecan, HAIP installation, cetuximab, Medtronic SynchroMed II Pump, Floxuridine, Dexamethasone, EKG, CT C/A/P, CT Angiogram (abdomen), Tumor and normal liver biopsy, Leucovorin
Device · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

NCT02115542
View directory record Official record
Conditions
Cancer of the Bile Duct
Interventions
Regorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 24, 2026, 8:04 PM EDT
Withdrawn Phase 3 Interventional

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

NCT03081039
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Carboplatin, Cisplatin, Gemcitabine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

NCT05919069
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AZD2693
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

NCT01312857
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
panitumumab, Randomization to No Panitumumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

NCT00091117
View directory record Official record
Conditions
Hepatic Complications, Malignant Neoplasm
Interventions
bortezomib, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Duarte, California • Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 24, 2026, 8:04 PM EDT
Terminated Phase 1 Interventional

Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors

NCT00955097
View directory record Official record
Conditions
Liver Tumors
Interventions
Definity®
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 24, 2026, 8:04 PM EDT
Active, not recruiting Phase 1 Interventional

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

NCT06710223
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SD-101, Cryotherapy, Tremelimumab, Durvalumab
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Not applicable Interventional

Endoscopic Ultrasound Guided Liver Biopsy

NCT03307811
View directory record Official record
Conditions
Hepatic Cancer, Hepatic Neoplasm, Hepatic Carcinoma
Interventions
22 gauge needle liver biopsy
Other
Lead sponsor
AdventHealth
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2019 · Synced Sep 24, 2026, 8:04 PM EDT
Completed No phase listed Observational

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

NCT05912933
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 24, 2026, 8:04 PM EDT
Not listed No phase listed Observational

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

NCT01341132
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
MRI Scan of the Liver enhanced with Eovist
Procedure
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

NCT03717935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
Essential Amino Acid (EAA) Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 24, 2026, 8:04 PM EDT
Not yet recruiting Phase 1 Interventional

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

NCT07715903
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions
Carfilzomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 24, 2026, 8:04 PM EDT
Terminated Phase 3 Interventional Results available

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

NCT01189227
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Postoperative chemotherapy, Perioperative chemotherapy
Procedure
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
283
States / cities
Antioch, California • Duarte, California • Fremont, California + 210 more
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 1 Interventional Results available

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

NCT02997176
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study

NCT02635347
View directory record Official record
Conditions
Liver Failure, Carcinoma, Hepatocellular
Interventions
Remote Ischemic Conditioning (RIC), Pneumatic tourniquet
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 24, 2026, 8:04 PM EDT
Recruiting No phase listed Observational

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

NCT06342414
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer, Primary Liver Carcinoma, Hepatic Cancer, Hepatic Carcinoma
Interventions
ELUCIDATE
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 24, 2026, 8:04 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

NCT02842125
View directory record Official record
Conditions
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Interventions
Ad-P53, Xeloda, Keytruda, Opdivo
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 1 Interventional

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

NCT00113113
View directory record Official record
Conditions
Tumors
Interventions
Rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Patient Portal Tool, E-assist, for Supporting CRC Screening

NCT02798224
View directory record Official record
Conditions
Colorectal Cancer
Interventions
e-assist: Colon Health, Healthwise Educational Program
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
1,826 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 24, 2026, 8:04 PM EDT
Recruiting No phase listed Observational

Neurofibromatosis (NF) Registry Portal

NCT01885767
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis
Interventions
Not listed
Lead sponsor
The Children's Tumor Foundation
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2050
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

NCT01177007
View directory record Official record
Conditions
Liver Neoplasms
Interventions
TheraSphere, Yttrium-90 glass Microspheres
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 24, 2026, 8:04 PM EDT
Active, not recruiting Phase 1 Interventional

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

NCT04518748
View directory record Official record
Conditions
Liver Malignancy
Interventions
Yttrium-90, Selective Internal Radiation Therapy, Stereotactic Body Radiation Therapy, PET/CT, Therasphere
Drug · Device · Radiation + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 24, 2026, 8:04 PM EDT
Completed Phase 1 Interventional

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

NCT02070549
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Trametinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
8
States / cities
Sacramento, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 24, 2026, 8:04 PM EDT